Vimla L. Naicker

Durban, ZN, South Africa

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial.

Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial.

Journal: Lancet (London, England)

Published: June 09, 2025

Neutralizing and binding antibodies are a correlate of risk of COVID-19 in the CoVPN 3008 study in people with HIV.

Neutralizing and binding antibodies are a correlate of risk of COVID-19 in the CoVPN 3008 study in people with HIV.

Journal: Nature communications

Published: April 09, 2025

Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women.

Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women.

Journal: The New England journal of medicine

Published: July 24, 2024

Hybrid versus vaccine immunity of mRNA-1273 among people living with HIV in East and Southern Africa: a prospective cohort analysis from the multicentre CoVPN 3008 (Ubuntu) study.

Hybrid versus vaccine immunity of mRNA-1273 among people living with HIV in East and Southern Africa: a prospective cohort analysis from the multicentre CoVPN 3008 (Ubuntu) study.

Journal: EClinicalMedicine

Published: July 19, 2024

Safety, effectiveness and immunogenicity of heterologous mRNA-1273 boost after prime with Ad26.COV2.S among healthcare workers in South Africa: The single-arm, open-label, phase 3 SHERPA study.

Safety, effectiveness and immunogenicity of heterologous mRNA-1273 boost after prime with Ad26.COV2.S among healthcare workers in South Africa: The single-arm, open-label, phase 3 SHERPA study.

Journal: PLOS global public health

Published: June 02, 2024

Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1-2 randomized double-blind placebo-controlled trial.

Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1-2 randomized double-blind placebo-controlled trial.

Journal: PLOS global public health

Published: May 10, 2024

Factors associated with reactogenicity to an investigational HIV vaccine regimen in HIV vaccine trials network 702.

Factors associated with reactogenicity to an investigational HIV vaccine regimen in HIV vaccine trials network 702.

Journal: Vaccine

Published: February 19, 2024

Tenofovir alafenamide: An initial experience at Groote Schuur Hospital, Cape Town, South Africa.

Tenofovir alafenamide: An initial experience at Groote Schuur Hospital, Cape Town, South Africa.

Journal: South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde

Published: February 01, 2022

Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults.

Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults.

Journal: The New England journal of medicine

Published: March 24, 2021

Sustained reduction in antibiotic consumption in a South African public sector hospital; Four year outcomes from the Groote Schuur Hospital antibiotic stewardship program.

Sustained reduction in antibiotic consumption in a South African public sector hospital; Four year outcomes from the Groote Schuur Hospital antibiotic stewardship program.

Journal: South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde

Published: January 30, 2017

A demonstration of the similiarities and differences in bone marrow morphology with nontuberculous mycobacterial infections.

A demonstration of the similiarities and differences in bone marrow morphology with nontuberculous mycobacterial infections.

Journal: International journal of laboratory hematology

Published: January 17, 2014

Showing 1-11 of 11

Last Updated: 09/26/2026